CDNA
Price
$25.29
Change
+$0.23 (+0.92%)
Updated
Jun 23, 04:04 PM (EDT)
Capitalization
1.3B
37 days until earnings call
Intraday BUY SELL Signals
RPID
Price
$1.70
Change
-$0.00 (-0.00%)
Updated
Jun 23, 04:15 PM (EDT)
Capitalization
84.95M
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDNA vs RPID

CDNA vs RPID Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CDNA vs. RPID commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a StrongBuy and RPID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (CDNA: $25.07 vs. RPID: $1.71)
Brand notoriety: CDNA and RPID are both not notable
CDNA represents the Medical Specialties, while RPID is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: CDNA: 95% vs. RPID: 104%
Market capitalization -- CDNA: $1.3B vs. RPID: $84.95M
CDNA [@Medical Specialties] is valued at $1.3B. RPID’s [@Medical/Nursing Services] market capitalization is $84.95M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $152.98B to $0. The average market capitalization across the [@Medical Specialties] industry is $15.2B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileRPID’s FA Score has 0 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • RPID’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDNA and RPID are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 4 TA indicator(s) are bullish while RPID’s TA Score has 4 bullish TA indicator(s).

  • CDNA’s TA Score: 4 bullish, 4 bearish.
  • RPID’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CDNA and RPID are a good buy in the short-term.

Price Growth

CDNA (@Medical Specialties) experienced а +4.11% price change this week, while RPID (@Medical/Nursing Services) price change was -0.87% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.

Reported Earning Dates

CDNA is expected to report earnings on Jul 30, 2026.

RPID is expected to report earnings on Jul 31, 2026.

Industries' Descriptions

@Medical Specialties (+0.45% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Medical/Nursing Services (-0.22% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($1.3B) has a higher market cap than RPID($84.9M). CDNA YTD gains are higher at: 33.068 vs. RPID (-41.207). CDNA has higher annual earnings (EBITDA): 5.54M vs. RPID (-43.61M). CDNA has more cash in the bank: 187M vs. RPID (41.2M). RPID (24.1M) and CDNA (24.5M) have identical debt. CDNA has higher revenues than RPID: CDNA (413M) vs RPID (30.5M).
CDNARPIDCDNA / RPID
Capitalization1.3B84.9M1,525%
EBITDA5.54M-43.61M-13%
Gain YTD33.068-41.207-80%
P/E Ratio14.89N/A-
Revenue413M30.5M1,354%
Total Cash187M41.2M454%
Total Debt24.5M24.1M102%
FUNDAMENTALS RATINGS
CDNA: Fundamental Ratings
CDNA
OUTLOOK RATING
1..100
40
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
81
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CDNARPID
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 16 days ago
89%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CDNA
Daily Signal:
Gain/Loss:
RPID
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MITBX35.38N/A
N/A
MFS Massachusetts Investors Tr B
BRWTX29.27N/A
N/A
MFS Blended Research Growth Eq R3
MAMVX17.73N/A
N/A
MoA Mid Cap Value Fund
VSMVX481.24N/A
N/A
Vanguard S&P Small-Cap 600 Val Idx Instl
CAISX14.90N/A
N/A
Calamos International Small Cap Gr A

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with BLFS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then BLFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-4.24%
BLFS - CDNA
38%
Loosely correlated
-4.42%
ABT - CDNA
37%
Loosely correlated
-0.66%
ADPT - CDNA
36%
Loosely correlated
-0.86%
VCYT - CDNA
34%
Loosely correlated
-0.82%
HBIO - CDNA
32%
Poorly correlated
+4.77%
More

RPID and

Correlation & Price change

A.I.dvisor tells us that RPID and QSI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RPID and QSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPID
1D Price
Change %
RPID100%
-0.29%
QSI - RPID
32%
Poorly correlated
-7.79%
ISRG - RPID
30%
Poorly correlated
-0.94%
MBOT - RPID
28%
Poorly correlated
-0.54%
CDNA - RPID
27%
Poorly correlated
-4.24%
GH - RPID
27%
Poorly correlated
-2.24%
More